| Reference |
Targeted therapy |
Number of patients (ratio) |
Patient population |
Response rate (95% CI) |
Median PFS |
Median OS |
6-month OS rate |
12-month OS rate |
| Chapman 2011 |
Vemurafenib |
675 (1:1) |
Previously untreated |
48% (42–55) |
6.9 months |
13.6 months |
84% |
56% |
| Dacarbazine |
5% (3–9) |
1.6 months |
9.7 months |
64% |
44% |
| Hauschild 2012 |
Dabrafenib |
250 (3:1) |
Previously
untreated
(except HD IL-2) |
50% (42–57) |
5.1 months |
18.2 months |
NR |
NR |
| Dacarbazine |
6% (2–16) |
2.7 months |
15.6 months |
NR |
NR |
| Robert 2012 |
Trametinib |
322 (2:1) |
One previous treatment allowed, except BRAF or MEK inhibitors or ipilimumab |
22% (17–22) |
4.8 months |
NR |
81% |
NR |
| Dacarbazine or paclitaxel |
8% (4–15) |
1.5 months |
NR |
67% |
NR |
| Flaherty 2012 |
Dabrafenib+trametinib (150 mg/1mg) |
247 (1:1:1) |
One previous treatment
allowed, except BRAF inhibitor |
50% (36-64) |
9,2 months |
NR |
NR |
26% |
| Dabrafenib+trametinib (150 mg/2mg) |
76% (62-86) |
9.4 months |
NR |
NR |
41% |
| Dabrafenib |
54% (40-67) |
5.8 months |
NR |
NR |
9% |
| Robert 2012 |
Selumetinib+Dacarbazina |
91 (1:1) |
Previously untreated |
40% (18-45) |
5.6 months |
13.9 months |
40% |
NR |
| Dacarbazina |
26% (12-46) |
3 months |
10.3 months |
22% |
NR |
